6.
Kreek M, Vocci F
. History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat. 2002; 23(2):93-105.
DOI: 10.1016/s0740-5472(02)00259-3.
View
7.
Kerensky T, Larochelle M, Fan S, Kosakowski S, Wason K, Walley A
. Non-prescription Fentanyl Positive Toxicology: Prevalence, Positive Predictive Value of Fentanyl Immunoassay Screening, and Description of Co-substance Use. J Addict Med. 2020; 15(2):150-154.
DOI: 10.1097/ADM.0000000000000723.
View
8.
Mitra S, Boyd J, Wood E, Grant C, Milloy M, DeBeck K
. Elevated prevalence of self-reported unintentional exposure to fentanyl among women who use drugs in a Canadian setting: A cross-sectional analysis. Int J Drug Policy. 2020; 83:102864.
PMC: 7669704.
DOI: 10.1016/j.drugpo.2020.102864.
View
9.
Rosenblum A, Parrino M, Schnoll S, Fong C, Maxwell C, Cleland C
. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007; 90(1):64-71.
DOI: 10.1016/j.drugalcdep.2007.02.012.
View
10.
Marshall T, Viste D, Jones S, Kim J, Lee A, Jafri F
. Beliefs, attitudes and experiences of virtual overdose monitoring services from the perspectives of people who use substances in Canada: a qualitative study. Harm Reduct J. 2023; 20(1):80.
PMC: 10290798.
DOI: 10.1186/s12954-023-00807-9.
View
11.
Sellen K, Markowitz B, Parsons J, Leece P, Handford C, Goso N
. Considerations for the design of overdose education and naloxone distribution interventions: results of a multi-stakeholder workshop. BMC Public Health. 2023; 23(1):888.
PMC: 10183687.
DOI: 10.1186/s12889-023-15554-6.
View
12.
Freiermuth C, Ancona R, Brown J, Punches B, Ryan S, Ingram T
. Evaluation of a large-scale health department naloxone distribution program: Per capita naloxone distribution and overdose morality. PLoS One. 2023; 18(8):e0289959.
PMC: 10420337.
DOI: 10.1371/journal.pone.0289959.
View
13.
Lemen P, Garrett D, Thompson E, Aho M, Vasquez C, Park J
. High-dose naloxone formulations are not as essential as we thought. Harm Reduct J. 2024; 21(1):93.
PMC: 11089786.
DOI: 10.1186/s12954-024-00994-z.
View
14.
Tilhou A, Birstler J, Baltes A, Salisbury-Afshar E, Malicki J, Chen G
. Characteristics and context of fentanyl test strip use among syringe service clients in southern Wisconsin. Harm Reduct J. 2022; 19(1):142.
PMC: 9753354.
DOI: 10.1186/s12954-022-00720-7.
View
15.
Grace Rose C, Kulbokas V, Carkovic E, Lee T, Pickard A
. Contextual factors affecting the implementation of drug checking for harm reduction: a scoping literature review from a North American perspective. Harm Reduct J. 2023; 20(1):124.
PMC: 10478363.
DOI: 10.1186/s12954-023-00856-0.
View
16.
Crocombe R, Giuntini G, Schiering D, Profeta L, Hargreaves M, Leary P
. Field-portable detection of fentanyl and its analogs: A review. J Forensic Sci. 2023; 68(5):1570-1600.
DOI: 10.1111/1556-4029.15355.
View
17.
Mattson C, Tanz L, Quinn K, Kariisa M, Patel P, Davis N
. Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths - United States, 2013-2019. MMWR Morb Mortal Wkly Rep. 2021; 70(6):202-207.
PMC: 7877587.
DOI: 10.15585/mmwr.mm7006a4.
View
18.
Twillman R, Dawson E, LaRue L, Guevara M, Whitley P, Huskey A
. Evaluation of Trends of Near-Real-Time Urine Drug Test Results for Methamphetamine, Cocaine, Heroin, and Fentanyl. JAMA Netw Open. 2020; 3(1):e1918514.
PMC: 6991312.
DOI: 10.1001/jamanetworkopen.2019.18514.
View
19.
Martinez S, Jones J, Brandt L, Campbell A, Abbott R, Comer S
. The Increasing Prevalence of Fentanyl: A Urinalysis-Based Study Among Individuals With Opioid Use Disorder in New York City. Am J Addict. 2020; 30(1):65-71.
PMC: 7816517.
DOI: 10.1111/ajad.13092.
View
20.
Arendt D
. Expanding the accessibility of harm reduction services in the United States: Measuring the impact of an automated harm reduction dispensing machine. J Am Pharm Assoc (2003). 2022; 63(1):309-316.
PMC: 9870941.
DOI: 10.1016/j.japh.2022.10.027.
View